期刊
MOLECULAR BIOTECHNOLOGY
卷 -, 期 -, 页码 -出版社
SPRINGERNATURE
DOI: 10.1007/s12033-023-00741-y
关键词
Single-chain fragment variable; gmLAB; Receptor-binding domain; COVID-19; SARS-CoV-2
In this study, a scFv based on the amino acid sequence of CC12.1 was designed to bind to the RBD of SARS-CoV-2 and enter cells through ACE2 receptors. Compared with the original antibody, scFv has the advantages of high tissue penetration and low production cost. gmLAB were constructed to incorporate the designed scFv and could be used as microbial therapeutics against COVID-19.
SARS-CoV-2 enters cells via binding of the surface-exposed spike protein RBD to host cell ACE2 receptors. Therefore, in this study, we designed a scFv (single-chain fragment variable) based on the amino acid sequence of CC12.1, a neutralizing antibody found in the serum of patients with COVID-19. scFv is a low-molecular-weight antibody designed based on the antibody-antigen recognition site. Compared with the original antibody, scFv has the advantages of high tissue penetration and low production cost. In this study, we constructed gmLAB (genetically modified lactic acid bacteria) by incorporating the designed scFv into a gene expression vector and introducing it into lactic acid bacteria, aiming to develop microbial therapeutics against COVID-19. In addition, gmLAB were also constructed to produce GFP-fused scFv as a means of visualizing scFv. Expression of each scFv was confirmed by Western blotting, and the ability to bind to the RBD was investigated by ELISA. This study is the first to design a scFv against the RBD of SARS-CoV-2 using gmLAB and could be applied in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据